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Background: Patients with human papillomavirus (HPV) infection are at risk of developing cancer later in their life.
Current research estimates the prevalence of genital HPV infection and explores the factors that are associated with
the infection.
Findings: The National Health and Nutrition Examination Survey 2007–2010 was used in this research study. The
study population included females in the United States aged 18–59 years. The weighted prevalence of HPV
infection was 41.9%. An estimated 59.4% of non-Hispanic black females had HPV infection. In a multivariate analysis,
number of sexual partners, race, age, education level, marital status, income, smoking, and insurance status were
associated with HPV infection. HPV infection was 5.77 times more likely for women with >11 sexual partners
compared to women with 0–1 partners. Non-Hispanic black females were 1.87 times more likely to have HPV
infection compared to non-Hispanic white females. Participants with only a high school degree had a 58%
increased prevalence compared to college-educated women. Uninsured women had a 39% increased prevalence
compared to those with insurance.
Conclusion: This study found that 41.9% of U.S. females aged 18–59 years tested positive for genital HPV infection.
We determined that individuals with more sexual partners, with a lower education level, with non-Hispanic black
race, and with no insurance were the populations at greatest risk. It is necessary to continue monitoring the
prevalence of this infection in the general population to provide a basis for effective treatment and prevention in
the target populations.
Keywords: Human Papillomavirus, Sexual behaviors, Prevalence Ratio, SurveyFindings
Genital human papillomavirus (HPV) is the most com-
mon sexually transmitted infection in the United States.
HPV includes a group of more than 150 related viruses.
Many of these viruses can be easily spread through dir-
ect skin contact during sexual intercourse [1]. More than
50% of individuals engaging in sexual activities are in-
fected with at least one type of HPV in their lifetime. An
estimated 42.5% of U.S. females aged 14–59 years had a
genital HPV infection in 2003–2006 [2]. Some patients
with HPV infection can be restored back to health, while
infection progresses to cancer in others [3].* Correspondence: rshi@lsuhsc.edu
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unless otherwise stated.More than 40 HPV types can infect the genital areas
of men and women [4]. These types can be classified as
high-risk, probable high-risk, low-risk, and undetermined
risk for the development of cervical cancer. Low-risk types
(HPV 6, 11) are mostly associated with genital warts.
High-risk types (HPV 16, 18) can contribute to precancer-
ous lesions, low-grade cervical intraepithelial lesions and
high-grade cervical intraepithelial lesions, as well as ano-
genital cancers [5]. HPV infection is a major cause of
cervical cancer [6], and 11,818 women in the U.S. were di-
agnosed with cervical cancer in 2010 [7].
The primary goals of our current research are to iden-
tify the potential factors associated with HPV infection
and to estimate the prevalence of infection for U.S. fe-
males from 2007 to 2010. Eventually, we aim to help cre-
ate programs targeting high-prevalence populations to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cervical cancer.
Methods and materials
Data was obtained from the National Health and Nutri-
tion Examination Survey (NHANES) 2007–2010 [8]. The
survey data includes information about demographic and
socioeconomic status, mental health, and dental health, as
well as physiological and laboratory measurements. The
survey interviews about 12,000 people biannually.
Survey design and population
The NHANES used a multistage probability sample de-
sign to select the participants. Consenting participants
completed a household interview followed by a physical
examination and interviews at a Mobile Examination
Center (MEC). Non-Hispanic (NH) black and low income
groups were oversampled in the NHANES to allow for an
accurate statistical estimation in these population groups
[9]. The protocol was approved by the National Center for
Health Statistics (NCHS) institutional review board. Fur-
ther information regarding study design and methods for
oversampling is available on the NHANES website [8].
From 2007 to 2010, 10,010 females of all ages were
interviewed. The combined unweighted household inter-
view response rate for that period was 78.9%; the exam-
ination response rate was 76.3%. All females aged 18–59
years (n = 4242) who visited the MEC were asked to self-
collect a cervicovaginal swab sample. Out of all samples
collected, 3738 (88.1%) were reported as positive or
negative and were used in the final analysis. Combining
the data for years 2007 through 2010 was justified. There
was no significant difference in HPV prevalence bet-
ween 2007–2008 and 2009–2010 for all but 5 of 37
HPV types, as detected by the Linear Array assay (data
not shown).
Demographic and behavioral data
Demographic information, including gender, age, race,
education, marital status, and country of birth, was ob-
tained from all participants during the household inter-
views. The poverty index was calculated according to the
U.S. Census definition. This method divides total family
income by the poverty threshold after adjusting for fam-
ily size at the time of the interview.
Sexual history information, including if the partici-
pant had ever had sex and the age of first sexual experi-
ence, was self-reported by participants using an audio
computer-assisted self-interview. Respondents who re-
ported having sex (described as vaginal, oral, or anal)
were asked additional questions about their lifetime sexual
history and about any sexual encounters in the prior
12 months. These additional questions addressed number
of sexual partners, sexual orientation, and condom usage.Specimen collection and processing, laboratory methods
As described by Dunne et al. [10], self-collected cervicova-
ginal swab samples were obtained from female partici-
pants aged 18–59 who had an examination in the MEC.
Swabs were given to the NHANES personnel, stored
at room temperature, and mailed within 1 week to the
Centers for Disease Control and Prevention (CDC) la-
boratory. There, they were kept at 4°C and extracted
within 1 month of collection.
Multiplex polymerase chain reaction (PCR) was used
for detection of 37 HPV types within the Alphapapillo-
mavirus genera. Samples were reported as HPV positive
if any of the 37 HPV deoxyribonucleic acid (DNA) types
were detected, including high-risk (16, 18, 26, 31, 33, 35,
39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) and low-risk
(6, 11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 82
subtype IS39, 83, 84, 89) types. If the strips were positive
for any of the types, the sample was coded as positive. If
the strips were negative for all of the types and beta-
globin was detected, the sample was coded as negative.
If there was no beta-globin present in the sample and no
HPV type was detected, the sample was coded as inad-
equate [8,11-14].
Statistical analysis
We estimated the overall prevalence of infection for any
HPV type with respect to sociodemographic and sexual
behavioral characteristics. Due to the complexity of the
design, all estimates were measured using 4-year MEC
sample weights provided by NCHS to account for the
unequal probabilities of selection and adjustment for
nonresponse. The weighting methodology has been de-
scribed previously [10]. Taylor series linearization was
used to estimate variance in a complex cluster survey
design [15]. Confidence intervals (CIs) were calculated
using a logit transformation with the standard error of
the logit prevalence based on the delta method and ap-
plying SUDAAN estimated standard errors [16].
The Wald χ2 statistic was used to assess bivariate as-
sociation between HPV and sociodemographic or behav-
ioral characteristics. No adjustments were made to the
p-values for multiple comparisons. An unconditional lo-
gistic regression model was used to determine associa-
tions between genital HPV infection and these factors.
Variables for adjustment in multivariate logistic regres-
sion models were selected based on bivariate associa-
tions with p-values <0.2. Goodness of fit for the final step
of the model was assessed using the Hosmer-Lemeshow
Satterthwaite adjusted F test.
SAS software version 9.4 for Windows (SAS Institute
Inc. Gary, North Carolina) and SAS callable SUDAAN
11.0.1 [17] were used for the statistical analyses. Two-
sided p-values less than 0.05 were considered statistically
significant.
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HPV types and species by oncogenic risk category are pre-
sented in Figure 1. In the NHANES 2007–2010, there
were 3738 females aged 18 to 59 years with an HPV evalu-
ation result in the final analysis. The 37 HPV types were
grouped as high-risk (Figure 1 Left Panel) or low-risk
(Figure 1 Right Panel). The prevalence of high-risk HPV
types 33 and 58 was less than 2%; HPV strains 16 and 18
had a prevalence of 4.92% and 1.77%, respectively. HPV
strain 53 had the highest prevalence of 6.26% in the high-
risk HPV category, and HPV strain 62 had the highest
prevalence of 5.93% in the low-risk category.
In a univariate analysis (Table 1), the overall weighted
prevalence of HPV infection was 41.9%. An estimated
59.4% NH black females and 38.7% of NH white females,
the lowest prevalence, were positive for HPV. There was
a statistically significant difference between subjects of
different races. The Prevalence Ratio for NH black fe-
males was 2.3 times that of NH white females.
There was a lower trend of HPV infection with increased
age, higher education level, and decreased family poverty
level. There was a bimodal pattern in the prevalence ofFigure 1 HPV types and species by oncogenic risk category. Left panHPV for age, with a high HPV prevalence of 56.1% in the
18–24 age group and with a second peak in the 40–44 age
group. HPV prevalence was 48% for women with less than
a high school education, whereas it was 31.4% for those
with a college education. Participants living in a family with
an income-to-poverty ratio (PIR) of <130% showed a 55.3%
prevalence of HPV infection. In terms of marital status,
prevalence was lowest (29.4%) for married women and
highest (>47%) for women classified as single, divorced, or
never married.
The association of HPV infection with behavioral fac-
tors is presented in Table 2. Females who smoked <100
cigarettes in their lifetime (Prevalence Ratio [PR] = 0.52)
were less likely to have HPV infection. Females who did
not have health insurance (PR = 1.9) or a routine place
to receive health care (PR =1.39) were more likely to
have HPV infection.
Females who reported never having sex were 71% less
likely to have HPV infection compared to females who
reported having sex. The prevalence of HPV infection in-
creased 89% for females having sex before 16 years of age
compared to after 16. There was a trend of increasingel, High-Risk HPV Types. Right panel, Low-Risk HPV Types.
Table 1 Weighted prevalence of HPV infection among female participants ages 18–59 by sociodemographic
characteristics NHANES 2007-2010
Sample size % 95% CI of % HPV+ 95% CI of PR
HPV+ HPV- HPV+ Lower Upper p-value# PR Lower Upper
All 1716 2022 41.9 39.6 44.2
Race
NH White 676 916 38.7 36.0 41.5
<0.0001
1.00
NH Black 436 299 59.4 54.4 64.2 2.32 1.90 2.83
Mex. Amer. 321 457 41.9 38.1 45.7 1.14 0.97 1.34
Other 283 350 40.7 35.3 46.4 1.09 0.85 1.38
Age
18-24 383 287 56.1 51.4 60.7
<0.0001
1.00
25-29 222 192 50.8 45.9 55.6 0.81 0.64 1.01
30-34 189 244 40.1 33.8 46.7
<0.001*
0.52 0.39 0.70
35-39 203 267 38.3 33.6 43.2 0.49 0.36 0.65
40-44 182 295 34.5 30.4 38.9 0.41 0.33 0.53
45-49 227 256 44.4 39.2 49.8 0.63 0.48 0.81
50-54 172 266 33.4 27.1 40.4 0.39 0.29 0.53
55-59 138 215 34.0 27.3 41.4 0.40 0.29 0.56
Education
> = College 243 480 31.4 27.4 35.6
<0.0001
1.00
<High School 486 484 48.0 43.6 52.3 2.02 1.54 2.63
High School 430 418 47.5 42.2 52.8
<0.001*
1.98 1.54 2.54
Some College 554 637 43.5 39.3 47.9 1.69 1.34 2.13
Marital Status
Married 562 1154 29.4 26.8 32.2
<0.0001
1.00
Wid/Div/Sep 393 278 58.3 53.4 63.0 2.96 2.08 4.20
Never married 457 322 55.6 50.0 61.0 2.10 1.50 2.94
Living W Partner 188 157 55.2 47.1 63.1 3.00 2.46 3.66
Missing 116 111 46.7 39.3 54.3 3.35 2.68 4.19
Ratio of family income to poverty
PIR:> = 350% 343 620 33.3 29.4 37.4 <0.0001 1.00
PIR:130-349% 541 655 43.0 39.2 47.0
<0.001*
1.42 1.19 1.71
PIR <130% 691 581 55.3 51.9 58.6 2.33 1.90 2.84
Country of Birth
US 1338 1437 42.7 40.0 45.4
0.1095
1.00
Mexico 161 281 35.6 30.7 40.8 0.743 0.598 0.923
Other 217 304 39.1 33.0 45.6 0.863 0.651 1.142
#P-value: Chi-Square Test; *P-value (p-values for CMH trend analysis, without missing categories), PR: Prevalence Ratio.
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partners in their lifetime (or yearly). The prevalence of in-
fection was 8.9 times higher for women with >11 sexual
partners in their lifetime compared to women with 0–1
partners. This trend was noticed among all races. Overall,
NH black females showed the highest prevalence of HPV
infection regardless of their number of partners (Figure 2).
Compared to women who used a condom during sex,
those who did not use a condom had twice the prevalence
of HPV infection. Lastly, women who identified them-
selves as being ‘lesbian’ or ‘bisexual’ had a 72% increased
prevalence of HPV infection compared to those who iden-
tified as ‘straight.’
In a multivariate logistic regression analysis, adjusting
for other factors, the number of lifetime sexual partnershad a significant association with HPV infection. HPV
infection was 5.77 times more likely for women with >
11 partners compared to women with 0–1 partners.
NH black females were 1.87 times more likely to have
an HPV infection compared to NH white females. Age
was negatively associated with the prevalence of HPV,
except for an increased peak in the 44–49 age group.
Having a college degree and being married were also
associated with lower HPV prevalence. Family income-to-
poverty ratio, a habit of smoking cigarettes, and insurance
status remained significant factors associated with HPV
infection.
When the results were adjusted for other factors, coun-
try of birth, recreational drug usage, ever having sex, age
at first sexual encounter, condom usage during sex, and
Table 2 Weighted prevalence of HPV among female participants ages 18–59 by behavioral factors
Sample size % 95% CI of % HPV+ p-value# 95% CI
HPV+ HPV- HPV+ Lower Upper PR Lower Upper
Smoked ≥ 100 cigarettes in life
Yes 763 608 51.2 47.3 55.1
<.0001
1.00
No 838 1304 35.3 32.5 38.3 0.52 0.44 0.62
Missing 115 110 45.7 38.3 53.3 0.80 0.56 1.15
Drug Use
Yes 857 713 49.0 45.4 52.7
<.0001
1.00
No 642 1066 33.2 30.0 36.4 0.79 0.58 1.06
Missing 217 243 43.0 37.3 48.9 0.52 0.43 0.62
Covered by health insurance
Yes 1157 1494 38.5 35.6 41.5
<.0001
1.00
No 557 524 54.4 51.1 57.7 1.90 1.58 2.29
Routine place for health care
Yes 1443 1736 41.0 38.5 43.5
0.0057
1.00
No 273 285 49.0 43.6 54.5 1.39 1.10 1.75
Ever had vaginal, anal, or oral sex
Yes 1467 1659 42.6 40.2 45.1
<.0001
1.00
No 33 118 17.6 11.9 25.4 0.29 0.19 0.43
Missing 216 245 43.1 37.3 49.1 1.02 0.78 1.33
How old when first had sex
> = 16 years 489 357 54.5 50.0 58.8
<.0001
1.00
<16 years 976 1296 38.8 36.2 41.4 1.89 1.59 2.24
Missing 251 369 37.1 32.2 42.3 0.93 0.74 1.18
#male sex partners lifetime




2-3 264 429 31.2 27.2 35.5 2.61 2.05 3.32
4-5 298 289 45.8 39.6 52.1 4.87 3.51 6.75
6-10 422 306 54.3 49.5 59.1 6.85 5.40 8.69
11+ 334 180 60.7 55.5 65.6 8.90 6.41 12.35
Missing 259 304 42.3 37.4 47.4 4.23 3.08 5.81
#male sex partners yearly




1 929 1283 37.3 34.9 39.7 1.09 0.93 1.27
2 178 57 74.8 66.8 81.5 4.10 2.96 5.70
3+ 159 32 85.2 77.0 90.9 6.89 4.61 10.30
Missing 256 312 41.3 36.6 46.3 1.28 1.06 1.55
#times had sex without condom/year




<half of the time 185 123 58.6 51.6 65.2 1.10 0.88 1.38
half of the time 99 57 63.5 54.6 71.5 2.25 1.59 3.19
>half of the time 120 83 56.3 48.8 63.5 2.76 2.00 3.82
Always 546 716 38.6 35.3 42.0 2.05 1.48 2.84
Missing 478 687 37.1 33.7 40.6 0.94 0.79 1.12
Describe sexual orientation





133 111 54.4 46.2 62.4 1.72 1.26 2.36
missing 228 272 42.5 37.2 47.9 1.07 0.83 1.37
#P-value: Chi-Square Test; *P-value (p-values for CMH trend analysis, without missing categories), PR: Prevalence Ratio.
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infection.
Discussion and conclusion
From the NHANES 2007–2010 data set, we found that
the overall prevalence of genital HPV infection was41.9% (95% CI: 39.6-44.2%) in females aged 18–59 in
the United States. We compared this result with two
previous NHANES analyses observing data for females
in the United States. Our estimate was similar to the re-
sult of the first study, which found a 42.5% (95% CI:
40.3-44.7%) prevalence for females aged 14–59 in the
Figure 2 Weighted prevalence of genital HPV among female adult participants aged 18–59 by lifetime sexual partners and race.
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lapped, indicating no statistical difference between these
two estimations. Our estimate was higher than the re-
sult of the second study, which found a prevalence of
26.8% [10] among females, aged 14–59 in the 2003–
2004 data set. This discrepancy could be due to a
change in the laboratory methods to detect HPV DNA
resulting in increased sensitivity of the test [2,18,19].
In our study, there was a bimodal prevalence of genital
HPV for age, consistent with the same two previous
NHANES studies [2,10]. This may indicate increased
sexual activity in the 18–24 age group [20,21] causing
the transmission of HPV by sexual contact. The reason
for the increased prevalence in the 45–49 age group is
unclear. We speculate that it may be due to an increased
incidence [22], a difference in sexual behaviors across
birth cohorts [23], or a change in marital status.
HPV infection was associated with certain racial and
ethnic groups. NH black females had an increased pre-
valence even when controlling for factors such as num-
ber of sexual partners in their lifetime (Figure 2) or other
factors (Table 3). Interestingly, even in the group with 0–1
sexual partners, NH black females had twice the preva-
lence of HPV infection compared to other racial and eth-
nic groups. This indicates that number of sexual partners
is not the only factor that impacts the prevalence of HPV
infection.
Some studies have shown an inconsistent association
between education level and prevalence [24,25]. How-
ever, in others, education level was negatively associated
with HPV infection [2,10]. In our study, with increased
education, the prevalence of HPV infection decreased.We speculate that this trend could be connected to fac-
tors such as increased awareness of HPV or adoption
of safe sexual practices. Safe practices might include,
but are not limited to, regular usage of condoms and
limiting the number of sexual partners. Therefore, health
education interventions could be introduced to reduce
the HPV prevalence by increasing awareness, encour-
aging safe sex [26], teaching about the routes of HPV
transmission, and promoting the use of the HPV vac-
cine [27].
The number of sexual partners played a statistically
significant role in HPV infection. This finding mirrors
those seen in other studies [2,10]. We also found an as-
sociation of health insurance status with HPV infection.
A meta-analysis showed that cost of vaccination and lack
of insurance coverage are barriers that prevent women
from obtaining the vaccine [28]. Individuals with private
health insurance are more likely to hear about the HPV
vaccine and three times more likely to get the vaccine
compared to uninsured patients or those with public in-
surance plans [29]. In addition, poverty and having
smoked <100 cigarettes in their lifetime were associated
with HPV infection.
In conclusion, 41.9% of U.S. females aged 18–59
years tested positive for genital HPV infection. This
study found that an increased number of sexual part-
ners, a lower level of education, non-Hispanic black
race, and a lack of insurance were factors of concern
with HPV infection. Continuing to monitor the preva-
lence of HPV in the general population can establish
a basis for possible interventions focusing on at-risk
groups.
Table 3 Multivariate logistic regression analysis of HPV







Mex. Amer. 1.50 1.16 1.95
NH Black 1.87 1.45 2.42
Other 1.13 0.84 1.52
Age
18-24 1.00
25-29 0.81 0.57 1.15
30-34 0.52 0.36 0.76
35-39 0.52 0.36 0.75
40-44 0.46 0.33 0.63
44-49 0.76 0.53 1.09
50-54 0.48 0.34 0.68
55-59 0.59 0.39 0.87
Education
> = College 1.00
<High School 1.36 0.95 1.95
High School 1.58 1.22 2.05
Some College 1.13 0.89 1.43
Marital Status
Married 1.00
Living W Partner 1.47 1.02 2.10
Never Married 1.74 1.34 2.25
Wid/Div/Sep 2.27 1.72 3.00
Missing 29.66 1.93 456.93
Ratio of family income
to poverty
>350% 1.00
<130% 1.38 1.11 1.71
130-349% 1.06 0.87 1.29
Country of Birth
US 1.00
Mexico 0.81 0.57 1.15
Other 1.35 0.94 1.94
Smoked at least 100
cigarettes in life
> = 100 Cig/life 1.00
<100 Cig/life 0.78 0.62 0.99
Missing 0.03 0.00 0.40
Drug Use
Yes 1.00
No 1.06 0.85 1.31




No 1.39 1.12 1.73
Routine place to go
for healthcare
Yes 1.00
No 0.95 0.72 1.26
Ever had vaginal, anal,
or oral sex
Yes 1.00
No 0.58 0.15 2.17
Missing 0.96 0.18 5.17
Table 3 Multivariate logistic regression analysis of HPV
infection with sociodemographic and behavioral factors
(Continued)
Age when first had Sex
> = 16 years. 1.00
<16 years 0.94 0.79 1.12




2-3 1.99 1.46 2.72
4-5 3.69 2.62 5.21
6-10 4.87 3.54 6.71
11+ 5.77 3.64 9.15
Missing 15.21 5.12 45.18
#male sex partners/year
0 1.00
1 0.97 0.64 1.49
2 2.17 1.10 4.28
3+ 3.12 1.47 6.65
Missing 0.55 0.22 1.36
#times had sex without
condom/ year
Never 1.00
<Half of the time 1.18 0.80 1.74
Half of the time 1.23 0.74 2.07
>Half of the time 0.97 0.64 1.47
Always 1.06 0.78 1.44







Missing 1.43 0.74 2.74
#Prevalence Ratio (PR). If the 95% Confidence Interval of the PR does not
contain the value 1.0, the association between the HPV infection and factor is
statistically significant (p<0.05).
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